Sheridan Capital Partners has raised nearly $1.35 billion across two new healthcare funds: $1.1 billion for its fourth core healthcare fund and $245 million for its first dedicated healthcare IT fund. The headline is the size. For RCM, the more interesting signal is that the IT fund got done at all — despite limited partners openly questioning whether AI would disrupt traditional healthcare software.
Nearly $1.35 billion across Sheridan Capital Partners Fund IV and Sheridan Healthcare IT Fund I, according to The Wall Street Journal.
Sheridan's core Fund IV closed at $1.1 billion.
It had targeted $800 million.
According to The Wall Street Journal, Sheridan raised the fund in roughly 60 days.
The healthcare IT fund was different.
Sheridan Healthcare IT Fund I closed at $245 million and took more than a year to raise.
One of the reasons: investors were wrestling with a basic question now confronting almost every healthcare software company.
What happens to the software business model when AI can replicate more functionality, automate more workflow, and compress the value of standalone tools?
Sheridan raised the fund anyway.
That makes the story more important than another successful PE close.
AI did not eliminate investor interest in healthcare software. It changed the underwriting question. Capital is moving toward platforms with real workflow ownership, specialty depth, recurring revenue, embedded RCM, and a credible path to becoming more valuable as AI improves.
The first investments in the new IT strategy are telling.
Cadara, formerly National Care Systems, provides financial and billing software for skilled nursing and assisted-living facilities. Its platform supports billing precision, reimbursement workflows, payment tracking, insurance claims, regulatory compliance, and A/R improvement.
ICANotes is a behavioral-health EMR and practice-management platform that combines clinical documentation with billing and revenue-cycle tools.
PtEverywhere provides practice management, scheduling, clinical documentation, integrated payments, billing, and collections for outpatient physical therapy and rehabilitation providers.
These are not generic horizontal SaaS products.
They sit directly inside specialty healthcare workflows where clinical activity, reimbursement, compliance, and cash collection intersect.
That is the category PE increasingly seems willing to underwrite.
The new fund is not a sudden pivot into revenue cycle.
Sheridan has repeatedly invested in RCM and tech-enabled administrative businesses.
In 2025, the firm invested in National Care Systems, now Cadara, specifically describing it as an RCM software provider serving skilled nursing and assisted-living facilities.
In 2023, Sheridan acquired Future Care Consultants, an RCM and back-office services company that later became Focal Point Care.
In 2021, Sheridan invested in SimiTree, which provides RCM and operational services to home health and hospice agencies.
That pattern matters.
RCM is not a side category for Sheridan.
It is one of the recurring ways the firm has expressed its broader healthcare thesis.
Sheridan's main healthcare strategy targets founder-owned, entrepreneurially led North American healthcare businesses.
Its stated criteria include:
For the core strategy, Sheridan targets platform companies with roughly $5 million to $25 million of EBITDA and equity investments of $30 million to $150 million.
That puts a large number of scaled RCM, coding, billing, payment, denial-management, practice-management, and specialty administrative platforms directly in range.
The M&A market is often discussed from the seller's perspective.
Are valuations up?
Is AI hurting multiples?
Will strategic buyers still pay for services businesses?
But fundraising is the other side of the transaction.
No fund means no buyer.
No dry powder means no platform acquisition.
No platform means fewer add-ons.
Sheridan just added nearly $1.35 billion of fresh capital dedicated exclusively to healthcare.
That capital has to be deployed.
For RCM founders, that means the buyer universe is not shrinking simply because AI is changing the operating model.
It may be changing what buyers want.
The fundraising contrast between the two funds captures the current market almost perfectly.
Healthcare services capital was raised quickly.
Healthcare IT required more debate.
That is rational.
A software product that primarily packages workflow screens around functionality AI can easily reproduce faces real risk.
A software platform embedded deeply in clinical, billing, reimbursement, compliance, payment, or specialty operations is different.
Its value comes from more than features.
It owns:
AI can make that type of platform more valuable rather than less.
Greenberg Advisors recently counted 142 RCM and HCIT transactions in the first half of 2026, the most active first half since 2021.
The market has not stopped consolidating.
What is changing is the asset mix.
Buyers increasingly value:
specialty workflow ownership,
embedded distribution,
proprietary operational data,
tech-enabled services,
and software that sits close enough to reimbursement to create measurable financial outcomes.
Sheridan's new funds fit directly into that pattern.
The question is no longer simply, “Is this a healthcare software company?” It is, “What workflow does it own, how defensible is the distribution, and does AI expand or compress the value of that position?”
Sheridan has historically used add-on acquisitions as a major part of its value-creation model.
In 2025 alone, the firm completed nine add-ons across its portfolio.
Its RCM investments have followed the same logic.
When Sheridan acquired National Care Systems, the firm explicitly described add-ons as part of the strategy — both to expand services to existing customers and to enter adjacent customer groups.
That matters for smaller RCM companies.
A business does not need to be a $100 million platform to become strategically valuable.
It can be an add-on that brings:
that makes the larger platform stronger.
Fresh platform capital creates future add-on demand.
The $1.1 billion core fund is obviously larger.
But the $245 million healthcare IT fund may be the more interesting signal for RCAI readers.
It is Sheridan's first dedicated vehicle for the category.
It was raised in an environment where AI has made LPs more skeptical of software durability.
And Sheridan is already deploying it into vertical platforms where billing, reimbursement, documentation, and payments are part of the core workflow.
That is a deliberate bet.
The firm is not betting that AI leaves healthcare software unchanged.
It is betting that the right healthcare software businesses remain valuable even as AI rewrites the product layer.
Sheridan's fundraise is another piece of evidence that healthcare RCM and administrative infrastructure remain attractive private-equity markets.
But the underwriting logic is evolving.
Software alone is not enough.
Services alone are not enough.
AI alone is not enough.
The strongest assets increasingly combine:
workflow ownership + specialty depth + recurring revenue + distribution + reimbursement intelligence + AI leverage.
That is exactly what Sheridan's recent healthcare IT investments look like.
The private-equity appetite for RCM has not disappeared. The bar has simply moved higher.
And with nearly $1.35 billion of new Sheridan capital looking for healthcare businesses, there is now a lot more dry powder available to test that thesis.
Daily coverage of payer policy, denials, deals, private equity, and AI developments — written for people who live in revenue cycle.
Sources: The Wall Street Journal — Sheridan Capital Gathers Nearly $1.35 Billion for Two New Healthcare Funds · Sheridan Capital Partners strategy · Sheridan portfolio materials · RevCycleAI analysis · October 7, 2026